STOK as reported
Stoke Therapeutics, Inc. reported $32M of revenue over the trailing twelve months, −83% on the year before. 8 reported series are charted on this page, each one as filed.
$32M
Revenue, trailing twelve months · to Q1 2026 · −83% against the twelve months before
- Net Income
- −$170M
Net Income · −438% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$148M
Free Cash Flow · −313% year on year · trailing twelve months to Q1 2026
- Op Margin
- −1461%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $32M | −83% | Q1 2026 |
| Net Income | −$170M | −438% | Q1 2026 |
| EPS | −$2.81 | −451% | Q1 2026 |
| Op Margin | −1461% | n/a | Q1 2026 |
| Net Margin | −1366% | n/a | Q1 2026 |
| ROE | −4.0% | n/a | Q1 2026 |
| ROA | −3.8% | n/a | Q1 2026 |
| Free Cash Flow | −$148M | −313% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Stoke Therapeutics, Inc. (STOK) - Revenue & ProfitRevenue & ProfitStoke Therapeutics, Inc. (STOK)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com